The US is temporarily halting giving this vaccine, pending further study, because of the potential danger of blood clots. Six women developed a rare form of blood clots after receiving this vaccine and one died.
The acting FDA chief, Janet Woodcock, said: “We’re recommending this pause while we work together to full understand these events.” The decision was taken in coordination with the CDC.
US health agencies have recommended states pause the administration of the Johnson & Johnson coronavirus vaccine, after reports of rare and severe blood clots emerged in six women. More than 6.8m doses have been administered nationally.
The concerns mirror those of drugs agencies in Europe and Australia over the AstraZeneca vaccine, which has not been authorized in the US. There have been no significant safety concerns raised about the two other vaccines that make up the majority of US supply, from Pfizer-BioNTech and Moderna.
Woodcock said: “Right now, I’d like to stress these events appear to be extremely rare. However, Covid-19 vaccine safety is a top priority for the federal government. We take all reports of adverse events related to the vaccine very seriously.”
The FDA and CDC said in a joint statement: “People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their healthcare provider.”